



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

8th August, 2018

Corporate Relationship Department
The BSE Ltd.
Dalal Street, Fort
Mumbai 400 001.

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) Mumbai 400 051.

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir,

Sub:- Outcome of Board Meeting

We would like to inform you that the Board of Directors of the Company at their meeting held today have inter-alia approved the following businesses:

1. Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2018 prepared under Indian Accounting Standards (IND-AS) and as per Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Limited Review Report of the Statutory Auditors. Please find enclosed a copy of the same along with press release for your information and records.
2. Declaration of an interim dividend of Rs.1.50 ps. per equity share of Rs.2/- each (75%) for the financial year 2018-19. The date for taking a record of its shareholders eligible for the purpose of payment of interim dividend i.e. **Record date is fixed for 21st August, 2018.** The said interim dividend **pay-by-date is on or before 27th August, 2018.**
3. Board had authorised Mr.V.C.Nannapaneni, Chairman and Managing Director for finalizing the date, time, venue and Book Closure dates for 35th Annual General Meeting for the financial year 2017-18.

Thanking you,

Yours faithfully,

For NATCO Pharma Limited

M. Adinarayana

Company Secretary &

V.P.(Legal & Corp. Affairs)

Encl: as above